Literature DB >> 7788097

Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy.

R Kreis1, J Pietz, J Penzien, N Herschkowitz, C Boesch.   

Abstract

Localized proton MR spectroscopy was used to identify phenylalanine (PHE) and to quantitate its cerebral concentration in patients with type I phenylketonuria (PKU). Data acquisition was optimized for the detection of low-concentration metabolites, using a short TE (20 ms) double Hahn-echo localization sequence for large volumes within the head coil and for smaller volumes using a surface coil. Previously described methods to quantitate localized MR spectra were extended to cover the case of low-concentration metabolites, unevenly distributed in three brain compartments and measured in difference spectra only. PHE content was determined in difference spectra of four PKU patients with respect to normals and in one patient before and after an oral load of L-PHE. PHE concentrations of 0.3 to 0.6 mmol/kg brain tissue were obtained, resulting in a concentration gradient for PHE between blood and brain tissue of 2.4 to 3.0. No significant changes were found for the abundant metabolites in gray or white matter. Previously reported MRI changes were confirmed to be due to increased cerebro-spinal-fluid-like spaces.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7788097     DOI: 10.1006/jmrb.1995.1084

Source DB:  PubMed          Journal:  J Magn Reson B        ISSN: 1064-1866


  10 in total

Review 1.  MR spectroscopy and spectroscopic imaging of the brain.

Authors:  He Zhu; Peter B Barker
Journal:  Methods Mol Biol       Date:  2011

2.  Reproducibility measurement of glutathione, GABA, and glutamate: Towards in vivo neurochemical profiling of multiple sclerosis with MR spectroscopy at 7T.

Authors:  Hetty Prinsen; Robin A de Graaf; Graeme F Mason; Daniel Pelletier; Christoph Juchem
Journal:  J Magn Reson Imaging       Date:  2016-06-28       Impact factor: 4.813

3.  Brain phenylalanine concentration in the management of adults with phenylketonuria.

Authors:  R A Moats; R Koch; K Moseley; P Guldberg; F Guttler; R G Boles; M D Nelson
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

4.  Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.

Authors:  J Pietz; R Kreis; A Rupp; E Mayatepek; D Rating; C Boesch; H J Bremer
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

5.  Proton nuclear magnetic resonance measurement of p-boronophenylalanine (BPA): a therapeutic agent for boron neutron capture therapy.

Authors:  C S Zuo; P V Prasad; P Busse; L Tang; R G Zamenhof
Journal:  Med Phys       Date:  1999-07       Impact factor: 4.071

6.  Magnetic resonance imaging of the brain in adolescents with phenylketonuria and in one case of 6-pyruvoyl tetrahydropteridine synthase deficiency.

Authors:  J Pietz; U K Meyding-Lamadé; H Schmidt
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

7.  Biochemical, Metabolic, and Behavioral Characteristics of Immature Chronic Hyperphenylalanemic Rats.

Authors:  Gerald A Dienel; Nancy F Cruz
Journal:  Neurochem Res       Date:  2015-07-30       Impact factor: 3.996

Review 8.  Large neutral amino acids supplementation in phenylketonuric patients.

Authors:  J C Rocha; F Martel
Journal:  J Inherit Metab Dis       Date:  2009-05-13       Impact factor: 4.982

9.  Phenylalanine can be detected in brain tissue of healthy subjects by 1H magnetic resonance spectroscopy.

Authors:  J Pietz; T Lutz; K Zwygart; G F Hoffmann; F Ebinger; C Boesch; R Kreis
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

10.  The rs113883650 variant of SLC7A5 (LAT1) gene may alter brain phenylalanine content in PKU.

Authors:  Miroslaw Bik-Multanowski; Kinga Bik-Multanowska; Iwona Betka; Anna Madetko-Talowska
Journal:  Mol Genet Metab Rep       Date:  2021-03-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.